Showing 1841-1850 of 9327 results for "".
High Risk SCC: What Factors Predict Recurrence and Metastasis?
https://practicaldermatology.com/topics/general-topics/PD1208_12-php/22609/Data shed light on risk factors associated with aggressive SCC, allowing dermatologists to identify and properly follow high-risk patients.Verrucous Psoriasis: A Rare Variant Refractory to Topical Steroids
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/verrucous-psoriasis-a-rare-variant-refractory-to-topical-steroids/29204/In this case study, researchers present a patient with VP of the dorsal fingers that was initially diagnosed as psoriasis and treated with multiple topical steroids. Ultimately, the patient was refractory to steroid topical therapy and required consideration of alternative treatments for definitiveProfessionalism in the Workplace: Tips for Managers
https://practicaldermatology.com/topics/practice-management/professionalism-in-the-workplace-tips-for-managers/20514/Maintaining the highest possible level of professionalism can help new and seasoned managers navigate challenges and position themselves to take advantage of additional opportunities.Psoriasis Treatment in 2025: More Options, Better Outcomes
https://practicaldermatology.com/issues/august-2025/psoriasis-treatment-in-2025-more-options-better-outcomes/36706/We have better drugs to treat psoriasis than almost any other dermatologic disease state. For patients, it is an excellent time to have psoriasis.Systemic Corticosteroids, Chronic Inflammatory Skin Disease, and COVID-19: What Do We Know?
https://practicaldermatology.com/topics/infections-infectious-disease/systemic-corticosteroids-chronic-inflammatory-skin-disease-and-covid-19-what-do-we-know/23615/An assessment of the risk of COVID-19 infection imposed by systemic corticosteroid use in the setting of chronic inflammatory skin disease.Biologics in Psoriasis: The Next Generation
https://practicaldermatology.com/topics/psoriasis/biologics-in-psoriasis-the-next-generation/20807/Get familiar with the IL-23 monoclonal antibodies.2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.How Will Dermatologists Use ChatGPT?
https://practicaldermatology.com/topics/practice-management/how-will-dermatologists-use-chatgpt/23876/Dr. Patel explores the potential role of ChatGPT in clinical practice and academics.Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethMeet the New Crop of Pigment Correctors
https://practicaldermatology.com/topics/pigmentary-disorders/meet-the-new-crop-of-pigment-correctors/23767/Hydroquinone is no longer the only game in town. In fact, alternatives are now more readily available and show good efficacy.